Skip to main content
. 2023 Jun 21;24(5):821–835. doi: 10.1007/s40257-023-00782-8

Table 1.

Total number of patients in each subgroup

Variable Subgroups A2311 study A2310 study
LD HD LD HD
Age < 12 years 17 16 8 9
≥ 12 years 25 26 32 31
Bodyweight < 25 kg 8 5
25 to < 50 kg 13 12 17 15
≥ 50 kg 25 26 22 21

Patients < 25 kg received 75 mg in both secukinumab dose groups

HD high dose, LD low dose